We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+29.17%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$836M
AUM Growth
+$210M
Cap. Flow
+$82.2M
Cap. Flow %
9.84%
Top 10 Hldgs %
42.54%
Holding
96
New
9
Increased
7
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$15.2M
2
CLLS
Cellectis
CLLS
+$13.9M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.74M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.21M

Top Sells

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$7.23M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$5.84M
3
ARRY
Array Biopharma Inc
ARRY
+$3.88M
4
CRIS icon
Curis
CRIS
+$3.59M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$3.17M

Sector Composition

Rank Sector Weight
1 Healthcare 80.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.39B
$55.6M 6.65%
700,000
– –
DYAX
2
DELISTED
DYAX CORPORATION
DYAX
$52.7M 6.3%
1,400,000
– –
HRTX icon
3
Heron Therapeutics
HRTX
$94.1M
$45M 5.38%
1,685,719
– –
EGRX
4
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$35.5M 4.24%
400,000
+100,000
+33% +$7.9M
NBIX icon
5
Neurocrine Biosciences
NBIX
$18.7B
$34.2M 4.09%
603,900
-115,000
-16% -$5.84M
OMER icon
6
Omeros
OMER
$863M
$30.8M 3.69%
1,960,000
– –
ARDX icon
7
Ardelyx
ARDX
$1.25B
$26.8M 3.21%
1,481,075
– –
PTLA
8
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$25.7M 3.08%
500,000
– –
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
$25M 2.99%
757,475
– –
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
$24.3M 2.91%
37,978
+10,000
+36% +$5.52M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$27.4B
$23.1M 2.76%
245,000
+105,000
+75% +$9.74M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$18.4M 2.2%
315,000
+75,000
+31% +$3.72M
SRNE
13
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$18.3M 2.18%
2,095,334
– –
NVRO
14
DELISTED
NEVRO CORP.
NVRO
$17.9M 2.14%
265,386
– –
ACRS icon
15
Aclaris Therapeutics
ACRS
$743M
$17.5M 2.09%
+647,944
New +$12.6M
CBPO
16
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$15.9M 1.9%
111,500
– –
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.7M 1.87%
495,356
+240,356
+94% +$8.49M
MGNX icon
18
MacroGenics
MGNX
$240M
$15.5M 1.85%
+500,000
New +$15.2M
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$15.2M 1.82%
291,250
– –
CLLS
20
Cellectis
CLLS
$287M
$14.6M 1.74%
469,145
+457,845
+4,052% +$13.9M
DVAX
21
DELISTED
Dynavax Technologies
DVAX
$13.9M 1.66%
575,000
– –
NVAX icon
22
Novavax
NVAX
$1.22B
$13.4M 1.61%
80,000
– –
CHRS icon
23
Coherus Oncology
CHRS
$227M
$13.1M 1.56%
569,130
– –
NKTR icon
24
Nektar Therapeutics
NKTR
$2.41B
$12.9M 1.54%
51,010
+24,510
+92% +$5.04M
DXCM icon
25
DexCom
DXCM
$28.8B
$12.5M 1.5%
612,000
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Cormorant Asset Management held 96 positions worth $836M, up 34% from $626M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $82.2M of net new capital in Q4 2015, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was MacroGenics: 500,000 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $7.23M trimmed.

  • Cormorant Asset Management's largest Q4 2015 buy was MacroGenics: 500,000 shares worth $15.5M.
  • Cormorant Asset Management added most to Cellectis in Q4 2015, an estimated $13.9M increase.
  • Cormorant Asset Management's biggest Q4 2015 reduction was Regulus Therapeutics, cutting an estimated $7.23M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q4 2015, selling an estimated $3.88M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $836M portfolio in Q4 2015.
  • Cormorant Asset Management opened 9 new positions and closed 14 in Q4 2015.
  • Cormorant Asset Management's portfolio value rose 34% quarter-over-quarter to $836M.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.